Erlotinib Completed Phase 2 Trials for Adenomatous Polyposis Coli Prevention

IndicationsStatusPurposePhase
CompletedPrevention2
clinicaltrials.gov IdentifierTitleDrugs
NCT01187901A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients